Your browser doesn't support javascript.
loading
Objective sputum colour assessment and clinical outcomes in bronchiectasis: data from the European Bronchiectasis Registry (EMBARC).
Aliberti, Stefano; Ringshausen, Felix C; Dhar, Raja; Haworth, Charles S; Loebinger, Michael R; Dimakou, Katerina; Crichton, Megan L; De Soyza, Anthony; Vendrell, Montse; Burgel, Pierre-Regis; McDonnell, Melissa; Skrgat, Sabina; Maiz Carro, Luis; de Roux, Andres; Sibila, Oriol; Bossios, Apostolos; van der Eerden, Menno; Kauppi, Paula; Wilson, Robert; Milenkovic, Branislava; Menendez, Rosario; Murris, Marlene; Borekci, Sermin; Munteanu, Oxana; Obradovic, Dusanka; Nowinski, Adam; Amorim, Adelina; Torres, Antoni; Lorent, Natalie; Van Braeckel, Eva; Altenburg, Josje; Shoemark, Amelia; Shteinberg, Michal; Boersma, Wim; Goeminne, Pieter C; Elborn, J Stuart; Hill, Adam T; Welte, Tobias; Blasi, Francesco; Polverino, Eva; Chalmers, James D.
Afiliação
  • Aliberti S; Respiratory Unit, IRCCS Humanitas Research Hospital, Pieve Emanuele, Italy.
  • Ringshausen FC; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy.
  • Dhar R; Department of Respiratory Medicine and Infectious Diseases, Hannover Medical School, Hannover, Germany.
  • Haworth CS; Biomedical Research in End-Stage and Obstructive Lung Disease Hannover, German Center for Lung Research (DZL), Hannover, Germany.
  • Loebinger MR; European Reference Network on Rare and Complex Respiratory Diseases, Frankfurt, Germany.
  • Dimakou K; CK Birla Hospitals, Kolkata, India.
  • Crichton ML; Cambridge Centre for Lung Infection, Royal Papworth Hospital and University of Cambridge, Cambridge, UK.
  • De Soyza A; Royal Brompton and Harefield Hospitals and National Heart and Lung Institute, Imperial College London, London, UK.
  • Vendrell M; 5th Respiratory Department and Bronchiectasis Unit, "Sotiria" General Hospital of Chest Diseases Medical Practice, Athens, Greece.
  • Burgel PR; Division of Molecular and Clinical Medicine, University of Dundee, Ninewells Hospital and Medical School, Dundee, UK.
  • McDonnell M; Population and Health Science Institute, Newcastle University and NIHR Biomedical Research Centre for Ageing, Freeman Hospital, Newcastle, UK.
  • Skrgat S; Department of Pulmonology, Dr Trueta University Hospital, Girona Biomedical Research Institute (IDIBGI), University of Girona, Girona, Spain.
  • Maiz Carro L; Department of Respiratory Medicine and French Cystic Fibrosis National Reference Center, Hôpital Cochin, AP-HP, Paris, France.
  • de Roux A; Université Paris Cité, Inserm U1016, Institut Cochin, Paris, France.
  • Sibila O; Department of Respiratory Medicine, Galway University Hospital, Galway, Ireland.
  • Bossios A; University Clinic of Respiratory and Allergic Diseases Golnik, Golnik, Slovenia.
  • van der Eerden M; Medical Faculty, University of Ljubljana, Ljubljana, Slovenia.
  • Kauppi P; Division of Internal Medicine, Pulmonary Department, University Medical Centre Ljubljana, Ljubljana, Slovenia.
  • Wilson R; Chronic Bronchial Infection Unit, Pneumology Service, Ramón y Cajal Hospital, Alcalá de Henares University, Madrid, Spain.
  • Milenkovic B; Pneumologische Praxis am Schloss Charlottenburg, Berlin, Germany.
  • Menendez R; Servicio de Neumología, Instituto Clínico de Respiratorio, IDIBAPS, Hospital Clínic, University of Barcelona, Barcelona, Spain.
  • Murris M; CIBER de Enfermedades Respiratorias, Instituto de Salud Carlos III, Madrid, Spain.
  • Borekci S; Department of Respiratory Medicine and Allergy, Karolinska University Hospital, Stockholm, Sweden.
  • Munteanu O; Division of Lung and Airway Research, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
  • Obradovic D; Erasmus MC, Department of Respiratory Medicine, Rotterdam, The Netherlands.
  • Nowinski A; Heart and Lung Center, Helsinki, Finland.
  • Amorim A; Royal Brompton and Harefield Hospitals and National Heart and Lung Institute, Imperial College London, London, UK.
  • Torres A; Clinic for Pulmonary Diseases, University Clinical Center of Serbia, Belgrade, Serbia.
  • Lorent N; School of Medicine, University of Belgrade, Belgrade, Serbia.
  • Van Braeckel E; Pneumology Department, Hospital Universitario y Politécnico La Fe - Instituto de Investigación Sanitaria La Fe, Valencia, Spain.
  • Altenburg J; Department of Respiratory Diseases, CHU Toulouse, Toulouse, France.
  • Shoemark A; Department of Pulmonology Diseases, Cerrahpasa Medical Faculty, Istanbul University - Cerrahpasa, Istanbul, Turkey.
  • Shteinberg M; Pneumology/Allergology Division, University of Medicine and Pharmacy Nicolae Testemitanu, Chisinau, Moldova.
  • Boersma W; Faculty of Medicine Novi Sad, University of Novi Sad, Novi Sad, Serbia.
  • Goeminne PC; Institute for Pulmonary Diseases, Sremska Kamenica, Serbia.
  • Elborn JS; Department of Epidemiology, National Tuberculosis and Lung Diseases Research Institute, Warsaw, Poland.
  • Hill AT; Pulmonology Department, Centro Hospitalar Universitário S. João and Faculty of Medicine, University of Porto, Porto, Portugal.
  • Welte T; Servicio de Neumología, Instituto Clínico de Respiratorio, IDIBAPS, Hospital Clínic, University of Barcelona, Barcelona, Spain.
  • Blasi F; CIBER de Enfermedades Respiratorias, Instituto de Salud Carlos III, Madrid, Spain.
  • Polverino E; Department of Respiratory Diseases, University Hospitals Leuven, Leuven, Belgium.
  • Chalmers JD; Department of Internal Medicine and Paediatrics, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium.
Eur Respir J ; 63(4)2024 Apr.
Article em En | MEDLINE | ID: mdl-38609095
ABSTRACT

BACKGROUND:

A validated 4-point sputum colour chart can be used to objectively evaluate the levels of airway inflammation in bronchiectasis patients. In the European Bronchiectasis Registry (EMBARC), we tested whether sputum colour would be associated with disease severity and clinical outcomes.

METHODS:

We used a prospective, observational registry of adults with bronchiectasis conducted in 31 countries. Patients who did not produce spontaneous sputum were excluded from the analysis. The Murray sputum colour chart was used at baseline and at follow-up visits. Key outcomes were frequency of exacerbations, hospitalisations for severe exacerbations and mortality during up to 5-year follow-up.

RESULTS:

13 484 patients were included in the analysis. More purulent sputum was associated with lower forced expiratory volume in 1 s (FEV1), worse quality of life, greater bacterial infection and a higher bronchiectasis severity index. Sputum colour was strongly associated with the risk of future exacerbations during follow-up. Compared to patients with mucoid sputum (reference group), patients with mucopurulent sputum experienced significantly more exacerbations (incident rate ratio (IRR) 1.29, 95% CI 1.22-1.38; p<0.0001), while the rates were even higher for patients with purulent (IRR 1.55, 95% CI 1.44-1.67; p<0.0001) and severely purulent sputum (IRR 1.91, 95% CI 1.52-2.39; p<0.0001). Hospitalisations for severe exacerbations were also associated with increasing sputum colour with rate ratios, compared to patients with mucoid sputum, of 1.41 (95% CI 1.29-1.56; p<0.0001), 1.98 (95% CI 1.77-2.21; p<0.0001) and 3.05 (95% CI 2.25-4.14; p<0.0001) for mucopurulent, purulent and severely purulent sputum, respectively. Mortality was significantly increased with increasing sputum purulence, hazard ratio 1.12 (95% CI 1.01-1.24; p=0.027), for each increment in sputum purulence.

CONCLUSION:

Sputum colour is a simple marker of disease severity and future risk of exacerbations, severe exacerbations and mortality in patients with bronchiectasis.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Escarro / Bronquiectasia Limite: Adult / Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Escarro / Bronquiectasia Limite: Adult / Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article